Meissa Vaccines

Child with respiratory syncytial virus
#Immunology / Virology & Vaccines #Meissa Vaccines #Paediatrics #Phase I trial #Respiratory syncytial virus

‘Compelling’ data for paediatric live attenuated RSV vaccine

A new respiratory syncytial virus (RSV) vaccine candidate has achieved positive safety and immunogenicity results in a Phase I clinical study of RSV-naïve participants between the ages of six and 36 months. MV-012-968 is being developed by Meissa Vaccines as a needle-free, adjuvant-free vaccine to protect… Read More

#News